Medical Disclaimer

Plain reading

TitrateLab is not a doctor, a pharmacy, or a clinical research organization. We aggregate publicly-available data: third-party COAs, vendor pricelists, regulatory filings, community discussion. We publish editorial analysis on top of that data. None of it is medical advice, and none of it should be treated as a substitute for consultation with a licensed healthcare professional in your jurisdiction.

If you are considering using any compound discussed on this site for any purpose involving your own body — including dosing protocols, stack design, side-effect management, or "is this safe for me" judgment calls — speak to a doctor first.

What we do publish

• Vendor and batch quality data, sourced from independent third-party labs (Janoshik, Finnrick, LiquiLabs and others) and our own ingest pipeline. We surface what the labs found, not what those findings mean for your particular health context.
• Editorial analysis on vendor incidents, regulatory changes, and the structure of the grey-market peptide industry. This is journalism + data engineering, not clinical guidance.
• Community-aggregated discussion from public forums and Discord channels, summarized and cited. Community consensus is not medical consensus.
• Auto-ingested research literature (PubMed, ClinicalTrials.gov, EuropePMC, DailyMed, PubChem, LiverTox). We make these papers and trial registrations easier to find. We do not interpret them for your individual case.

What we don't publish

• Personal dosing recommendations. When community-sourced dosing ranges appear in our editorial content, they are reported as community consensus with explicit caveats — not as instructions.
• Diagnostic or therapeutic guidance. We will not tell you whether a compound is right for your condition, whether your side effects are normal, or whether you should adjust your protocol.
• Endorsements of self-administration. Most of the compounds we cover are not FDA-approved for human self-use, and many sit in regulatory grey zones whose contours change frequently. See the research-only framing below.

Regulatory context

Most peptides discussed on TitrateLab are categorized by the FDA as either Category 2 (under September 2023 reclassification) or otherwise restricted from compounding for human administration. The September 2023 reclassification of 17 peptides — including BPC-157, TB-500, and CJC-1295 — formally placed those compounds outside the legal compounding pathway for patient-specific use, although enforcement and regulatory reversals are ongoing (the July 23, 2026 PCAC consultation may revise this; see our research archive for the current state).

Other compounds we cover (the GLP-1/GIP/glucagon agonists like tirzepatide, retatrutide, semaglutide) are FDA-approved for specific prescribed indications via licensed pharmacies, but the grey-market versions sourced from research-chemical vendors are NOT what was approved. They are research-grade product, often manufactured outside US Good Manufacturing Practice (cGMP) standards, sometimes contaminated (see our recent JEEP T30 endotoxin entry for one documented example), and not legal for human self-administration.

Research-only use

The compounds tracked on this platform are for research use only. Bench research, in-vitro experiments, animal studies under appropriate ethical frameworks. We do not promote, encourage, or facilitate human self-administration of unapproved compounds.

We are aware that a meaningful fraction of the people who buy research-chemical peptides do so for personal use, off the books, in the absence of clear legal pathways for the same molecules through the licensed pharmacy system. We are not naive about this. Our position is that the existence of that off-books market is precisely why an audit trail like ours matters — so that the people making those decisions are doing so with the best possible data, including the data on what's contaminated and who has cycled through exit scams. That position is not the same as endorsing self-administration.

Adverse events

If you experience an adverse event you suspect is related to a research-chemical peptide:

1. Get medical attention first. Endotoxin exposure can present as fever, chills, hypotension, or worse; sterility failures can present as injection-site infections progressing to systemic symptoms; underdosing of GLP-1s does not cause the kind of acute presentation a doctor will recognize, but other quality failures can.
2. Tell your provider what you took, even if you didn't get it through prescription channels. Doctors are bound by patient-confidentiality rules, and the risk of withholding the information from a treating clinician far exceeds any embarrassment.
3. Report it to FDA's MedWatch (https://www.fda.gov/safety/medwatch) so it enters the national adverse-event reporting system. This is the mechanism that drives policy change.
4. Consider also documenting it in our community channel at discord.gg/biohacking, with the vendor and batch information if you have it. We aggregate these reports into our vendor incident archive when there's enough corroboration.

What this disclaimer is and isn't

It's: a clear statement of what TitrateLab is for (intelligence + audit trail) and what it isn't for (clinical guidance), so that visitors can calibrate their use of the site appropriately.

It isn't: a legal shield that absolves us from telling the truth about vendors, regulators, or the structural failures of the grey market. We will continue to publish what the data shows. The disclaimer here applies to medical interpretation; our editorial obligations to publish accurate, well-sourced reporting on the industry are separate.

Updating this disclaimer

This page is versioned. The version + last-updated date above this line are authoritative. If we materially change the medical disclaimer (e.g. adding a clinical-advisor program, expanding what kinds of guidance we publish, or narrowing our research-only framing), we'll bump the version number and note the change here.

Contact

For medical-disclaimer questions specifically, email legal@titratelab.com (placeholder pre-launch — the operator will publish the real address before the site goes live).

For general TitrateLab questions, the live community is at discord.gg/biohacking and editorial inquiries go to press@titratelab.com.

---

This is a "shell" disclaimer drafted before formal legal review. The substance is correct and reflects how we actually operate, but a lawyer will tighten the language before launch. If you're reading this AFTER launch and the version number above still ends in -shell, please flag it to us.